Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma

@article{Marone2019TezepelumabAN,
  title={Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma},
  author={Giancarlo Marone and Giuseppe Spadaro and Mariantonia Braile and Remo Poto and Gjada Criscuolo and Hadas Pahima and Stefania Loffredo and Francesca Levi-Schaffer and Gilda Varricchi},
  journal={Expert Opinion on Investigational Drugs},
  year={2019},
  volume={28},
  pages={931 - 940}
}
ABSTRACT Introduction: Thymic stromal lymphopoietin (TSLP) is overexpressed in the airways of severe asthmatics and is an upstream cytokine that orchestrates inflammatory responses in asthma. TSLP exerts its effects by binding to a high affinity heteromeric receptor complex composed of TSLPR and IL-7Rα. An association of polymorphisms in TSLP with airway hyperresponsiveness, IgE, eosinophilia and asthma has been documented. TSLP has been implicated in asthma pathophysiology. Tezepelumab is a… 
TSLP Inhibitors for Asthma: Current Status and Future Prospects
TLDR
Some critical aspects remain to be clarified before being able to define this approach as the one that will probably better help patients suffering from severe asthma because of its holistic effects, but new information suggests that targeting TSLP may be more likely to improve day-to-day asthma symptoms.
Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
TLDR
Preliminary results of randomized clinical trials suggest that tezepelumab is characterized by a good safety and efficacy profile in patients with severe, uncontrolled asthma.
Severe asthma: what is new in the new millennium.
TLDR
Novel anti-IL5 agents have changed the management of T2-high asthma resulting in improved disease control, QoL and lung function and importantly, fewer exacerbations, Nevertheless, there is still the need to find new treatments, particularly for T 2-low asthma, which remains a challenge.
Molecular Targets for Biological Therapies of Severe Asthma
TLDR
New therapeutic options make it possible to implement phenotype/endotype-specific treatments, that are delineating personalized approaches precisely addressing the individual traits of asthma pathobiology, allowing to successfully target the immune-inflammatory responses underlying uncontrolled T2-high asthma.
Phenotyping severe asthma: a rationale for biologic therapy
TLDR
The purpose of this review is to discuss the current knowledge about the molecular phenotypes of severe asthma, as well as the rationale underlying the use of existing biological drugs.
Advances in understanding of Netherton syndrome and therapeutic implications
TLDR
Improved understanding of NS pathogenesis has led to the successful use of repurposed biologics such as intravenous immunoglobulins and anti-IL-17A blockers, and specific KLK5 and/or KLK7 inhibitors represent the most promising disease-modifying treatments.
Anti-Interleukin Biologics for the treatment of the Atopic March Diseases
The atopic march refers to the natural history of allergic disorders as they develop from infancy to childhood. Classically, the atopic march begins with atopic dermatitis (AD), followed by food
Advances and Challenges of Antibody Therapeutics for Severe Bronchial Asthma
TLDR
Recent advancements in antibody therapeutics and novel findings related to the disease process for severe asthma are reviewed.
Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases
TLDR
Most common AE to biologic agents approved for asthma and allergic diseases are benign and tolerated, though long-term safety is lacking for most of them.
Biologics in food allergy: up-to-date
TLDR
The role of biologics as a treatment option in patients with IgE-mediated food allergy is focused on, characterized by their ability to inactivate the Th2 pro-inflammatory pathways.
...
1
2
3
...

References

SHOWING 1-10 OF 173 REFERENCES
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
TLDR
The use of blood eosinophils as a baseline biomarker could help to select patients with severe uncontrolled asthma who are likely to achieve benefits in asthma control with reslizumab, and represents one step closer to precision medicine.
Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma
TLDR
A fusion protein comprising a tandem of the TSLPR and IL-7Rα extracellular domains is introduced, which harnesses the mechanistic intricacies ofThe TSLP-driven receptor complex to manifest high antagonistic potency.
Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma.
TLDR
TSLP expression is increased in a subset of patients with severe asthma in spite of high-dose inhaled or oral corticosteroid therapy, and targeting TSLP might only be efficacious in the subset of asthma characterized by increased T SLP expression and T(H)2 inflammation.
Tezepelumab in Adults with Uncontrolled Asthma
TLDR
Among patients treated with long‐acting beta‐agonists and medium‐to‐high doses of inhaled glucocorticoids, patients who received tezepelumab had lower rates of clinically significant asthma exacerbations than those who received placebo, independent of baseline blood eosinophil counts.
Effects of an anti-TSLP antibody on allergen-induced asthmatic responses.
TLDR
Findings are consistent with a key role for TSLP in allergen-induced airway responses and persistent airway inflammation in patients with allergic asthma and whether anti-TSLP therapeutics will have clinical value cannot be determined from these data.
Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma
TLDR
A more detailed analysis of the immunological mechanisms underlying the pathogenesis of asthma shows interleukin 5 (IL-5) to be a crucial cytokine in several asthma phenotypes and exerts selective action on eosinophils, which sustain airway inflammation and worsen asthma symptoms and control.
Increased expression of thymic stromal lymphopoietin in induced sputum from asthmatic children.
TLDR
The increase in TSLP and TNF-α level observed in IS fluid was found to correlate with disease severity, and Regulation of T SLP pathway may be a therapeutic approach for asthma.
Eosinophils in the pathogenesis of paediatric severe asthma
TLDR
Data from children with severe asthma have shown that findings from adults cannot be translated to children, and that steroid-resistant eosinophilic inflammation appears central to the pathogenesis of paediatric disease.
T2-low asthma: current approach to diagnosis and therapy
TLDR
Asthma pathogenesis is characterized by two major endotypes, a T1-high featuring increased eosinophilic airway inflammation, and a T2-low endotype presenting with either neutrophilic or paucigranulocytic airwayinflammation and showing greater resistance to steroids.
Dupilumab in persistent asthma with elevated eosinophil levels.
TLDR
In patients with persistent, moderate-to-severe asthma and elevated eosinophil levels who used inhaled glucocorticoids and LABAs, dupilumab therapy, as compared with placebo, was associated with fewer asthma exacerbations when LABs and inhaled GLPAs were withdrawn, with improved lung function and reduced levels of Th2-associated inflammatory markers.
...
1
2
3
4
5
...